Shopping Cart
Remove All
Your shopping cart is currently empty
DMG-pSar25
Copy Product Info
🥰Excellent
Synonyms:
Catalog No. TYD-04046 Copy Product Info
🥰Excellent
DMG-pSar25 is a lipid composed of a DMG unit conjugated to a pSar25 polymer. DMG-pSar25 is utilized in RNA delivery research involving lipid nanoparticle formulation, where DMG-pSar25 serves as a PEG alternative and is studied for its effects on mRNA transfection efficiency, nanoparticle stability, and safety profile modulation in nucleic acid delivery systems.
DMG-pSar25
Cas No. 2936622-30-7
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $258 | - | In Stock | |
| 5 mg | $632 | - | In Stock | |
| 10 mg | $987 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Appearance:Solid
Color:White
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | DMG-pSar25 is a lipid composed of a DMG unit conjugated to a pSar25 polymer. DMG-pSar25 is utilized in RNA delivery research involving lipid nanoparticle formulation, where DMG-pSar25 serves as a PEG alternative and is studied for its effects on mRNA transfection efficiency, nanoparticle stability, and safety profile modulation in nucleic acid delivery systems. |
| In vitro | Methods：Lipid nanoparticles were prepared using DMG-pSar25, ALC-0159 and DMG-PEG2000 respectively. C2C12 and Hep3B cells were treated with these nanoparticles for 18 hours, and mRNA delivery efficiency as well as cell viability were detected. Results： 1.Compared with ALC-0159 control, DMG-pSar25 improved the mRNA delivery efficiency of ALC-0315-based lipid nanoparticles, with no significant change in cell viability. 2.When applied to SM-102-based lipid nanoparticles, DMG-pSar25 achieved comparable mRNA delivery efficiency and cell viability relative to DMG-PEG2000 control [1]. |
| In vivo | Methods：Healthy mice received a single intramuscular injection of 0.06 µg mRNA. The polyethylene glycol lipids in two types of lipid nanoparticles (LNPs) were replaced with DMG-pSar25. The in vivo mRNA delivery efficiency, immunogenicity and anti-PEG antibody production were evaluated. Results：After replacement in ALC-0315-based LNPs, the total in vivo mRNA delivery flux in mice increased by more than 5 times. For SM-102-based LNPs, the delivery efficiency was comparable to that of conventional PEG-modified LNPs. The two formulations exhibited similar immunogenicity, and DMG-pSar25 did not induce anti-PEG antibody production [1]. |
| Cas No. | 2936622-30-7 |
| Storage | Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol: 40 mg/mL, Sonication is recommended. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: DMG-pSar25 in vivo | DMG-pSar25 in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.